Skip to main content
VRAX
NASDAQ Life Sciences

Virax Sets Nov 27 Vote on 1-for-4 Reverse Split and 4x Authorized Share Increase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.6
Mkt Cap
$823.939K
52W Low
$0.503
52W High
$21.75
52W Position info
19% above low
Off High info
97% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

VRAX sits 19% above its 52-week low of $0.503 on light trading volume (0.1× avg).

Summary

Virax shareholders will vote November 27 on a 1-for-4 reverse split effective December 14, 2026 and an increase in authorized capital to 500 million shares — a Nasdaq minimum-bid defense paired with a large new pool of shares to issue.


Key Events · Corporate Governance and Compliance · VRAX

  • 1-for-4 Reverse Split Up for Vote

    Shareholders vote November 27, 2026 on consolidating every 4 ordinary shares of US$0.025 par into one share of US$0.10 par, effective December 14, 2026 or a later date accepted by Nasdaq.

  • Authorized Shares to Quadruple

    Authorized capital would rise from US$12,500,000 divided into 125,000,000 shares of US$0.10 par to US$50,000,000 divided into 500,000,000 shares, creating 375,000,000 new authorized shares for financing and business development.

  • No Nasdaq Cure Period Remaining

    Because a 25-for-1 consolidation was already effected June 26, 2026, a closing bid below $1.00 for 30 consecutive business days would make the company ineligible for any compliance period and trigger a Staff Delisting Determination.

  • Charter Rewrite Requires Two-Thirds

    Adopting the Fifth Amended and Restated Memorandum and Articles is a special resolution needing two-thirds of votes cast; the split and capital increase need only a simple majority.


Analysis · VRAX · Life Sciences

The vote matters because the split is a defensive move: with the stock at $0.60, below Nasdaq's $1.00 minimum bid, and a 25-for-1 consolidation already effected on June 26, 2026, a 30-day sub-$1.00 stretch would leave no compliance period at all — Nasdaq would issue a Staff Delisting Determination. Shareholders are being asked to approve a 1-for-4 consolidation effective December 14, 2026, and then immediately quadruple authorized capital to 500 million shares of US$0.10 par. That capital increase is the other half of the story: it hands management roughly 375 million new authorized shares to issue for 'basic financing needs' and business development, on top of an ATM with about $2.07 million of remaining capacity. Existing holders therefore face both a mechanical share-count reduction and a much larger pool of potential future dilution.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VRAX was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $823.9K. The 52-week trading range was $0.50 to $21.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VRAX - Latest Insights

VRAX
Aug 26, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $0.600 info
Change: -$2.36 (-80%) info
Market Cap: $823.939K info
VRAX
Jul 31, 2026, 7:44 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.94
Real-time Price: $0.600 info
Change: -$2.34 (-80%) info
Market Cap: $823.939K info
VRAX
Jul 24, 2026, 4:20 PM EDT
Filing Type: F-3
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $0.600 info
Change: -$2.65 (-82%) info
Market Cap: $823.939K info
VRAX
Jul 16, 2026, 7:31 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.11
Real-time Price: $0.600 info
Change: -$3.51 (-85%) info
Market Cap: $823.939K info
VRAX
Jul 10, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.05
Real-time Price: $0.600 info
Change: -$3.45 (-85%) info
Market Cap: $823.939K info